Utility of customized PEG linkers for the delivery of oligonucleotides without the use of transfection agents

Technical Proceedings of the 2008 NSTI Nanotechnology Conference and Trade Show, NSTI-Nanotech, Nanotechnology 2008

Volumn 2, Issue , 2008, Pages 372-374

  Zhao, Hong ^a   Reddy, Prasanna ^a   Xia, Jing ^a   Wang, Maoliang ^a   Sapra, Puja ^a   Bandaru, Raj ^a   Rubio, M Belen ^a   Wu, Dechun ^a   Zhu, Peifang ^a   Filpula, David ^a   Greenberger, Lee M ^a   Horak, Ivan D ^a  

^a Enzon Incorporated   (United States)

Author keywords

Antisense oligonucleotide (AS ODN); Customized PEG linker; Locked nucleic acid (LNA); mRNA down modulation; Poly(ethylene glycol) (PEG)

Indexed keywords

AUDIO FREQUENCY AMPLIFIERS; BINDING ENERGY; CHEMOTHERAPY; COMMERCE; EXHIBITIONS; FLUORESCENCE MICROSCOPY; HEALTH; IMAGING TECHNIQUES; LOW NOISE AMPLIFIERS; MICROSCOPIC EXAMINATION; MODULATION; NUCLEIC ACIDS; NUCLEOTIDES; OLIGONUCLEOTIDES; POLYETHYLENE GLYCOLS; RNA; TECHNOLOGY;

ANTISENSE OLIGONUCLEOTIDE (AS-ODN); ANTISENSE OLIGONUCLEOTIDES; BIO-DISTRIBUTION; CANCER.; CUSTOMIZED PEG LINKER; DOSE-DEPENDENT MANNER; IN FLUORESCENCE; IN-VITRO; LIFE SCIENCES; LIPOFECTAMINE; LOCKED NUCLEIC ACID; LOCKED NUCLEIC ACID (LNA); MRNA DOWN-MODULATION; MRNA EXPRESSION; NANO MOLAR; NANOMOLAR CONCENTRATIONS; POLY(ETHYLENE GLYCOL) (PEG); RNA ANTAGONISTS; SPECIFIC BINDING; TARGET BINDING; TRADE SHOWS; TRANSFECTION AGENTS; TUMOR ACCUMULATION;

NANOTECHNOLOGY;

EID: 52649102978     PISSN: None     EISSN: None     Source Type: Conference Proceeding    
DOI: None     Document Type: Conference Paper

References (8)

1. Zhao, H.; Greenwald, R. B.; Reddy, P.; Xia, J.; Peng, P. "A new platform for oligonucleotide delivery utilizing the PEG prodrug approach." Bioconjugate Chem. 2005, 16(4): 758-66.
2. Zhao, H.; Peng, P.; Longley, C.; Zhang, Y.; Borowski, V.; Mehlig, M.; Reddy, P.; Xia, J.; Borchard, G.; Lipman, J.; Benimetskaya, L.; Stein, C. A. "Delivery of G3139 using releasable PEG-linkers: impact on pharmacokinetic profile and antitumor efficacy" J. Control. Release. 2007, 119, 143-52.
3. Mae, M., Langel, U. "Cell Penetrating peptides as vectors for peptide, proteins and oligonucleotide delivery" Curr Opin Pharmacol., 2006, 6, 509-14.
4. P. Jarver, K.Langel, S. EI-Andaloussl and O. Langel, "Applications of cell-penetrating peptides in regulation of gene-expression". Biochem. Soc. Trans., 2007, (35), Pt4 7740-7746.
5. Zhao, X. B., Lee, R. J., "Tumor-selective targeted delivery of genes and antisense oligonucleotides via the folate receptor" Adv. Drug Deliv. Rev., 2004, 56, 1193-204.7.
6. Temming, K., Schifflers, R.M., Molema, G., Kok, R.J., "RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumor vasculature" Drug resist Updat. 2005, 8, 381-402.
7. Schrama, D., Reisfeld, R.A., Becker, J.C., "Antibody targeted drugs as cancer therapeutics" Nat. Rev. Drug Discov., 2006, 5, 147-59
8. Greenwald, R. B., and Zhao, H. (2007) "Poly (ethylene glycol) prodrugs: altered pharmacokinetics and pharmacodynamics" Prodrugs: Challenges and Rewards. Part 1 (Stella, V. J., Borchardt, R. T., Hageman, M. J., Oliyai, R., Maag, H., and Tilley, J. W., Eds.) pp 283-338, Chapter 2.3.1, Springer, United States of America